T-cell immunotherapy company Atara Biotherapeutics Inc (Nasdaq: ATRA) announced on Wednesday that the U.S. FDA has accepted its Biologics License Application (BLA) for tabelecleucel (tab-cel), a treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). The BLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of 15 January 2025.
If approved, tab-cel would be the first FDA-approved therapy for EBV+ PTLD. The acceptance of the BLA triggers a USD20m milestone payment from Pierre Fabre Laboratories, with an additional USD60m contingent upon FDA approval.
Tab-cel is an allogeneic, EBV-specific T-cell immunotherapy designed to target and eliminate EBV-infected cells. The BLA submission is backed by data from over 430 patients, including pivotal ALLELE study results showing a 48.8% Objective Response Rate (ORR) and a favorable safety profile.
The treatment has previously received Breakthrough Therapy Designation and orphan drug status from the FDA. Marketing authorization was granted under the brand name Ebvallo™ by the European Commission in December 2022, the UK Medicines and Healthcare Products Regulatory Agency in May 2023, and Swissmedic in May 2024.
Atara, headquartered in Southern California, leverages its T-cell immunotherapy platform to develop treatments for cancers and autoimmune diseases. The company is the first to receive regulatory approval for an allogeneic T-cell therapy.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals